HEARTWARE INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against HeartWare International, Inc.
February 09 2016 - 5:08PM
Business Wire
The law firm of Lieff Cabraser Heimann & Bernstein, LLP
reminds investors of the upcoming deadline to move for appointment
as lead plaintiff in securities class litigation brought on behalf
of investors who purchased or otherwise acquired the common stock
of HeartWare International, Inc. (“HeartWare” or the “Company”)
(Nasdaq:HTWR) between June 10, 2014 and January 11, 2016, inclusive
(the “Class Period”).
If you purchased or acquired HeartWare common stock during the
Class Period, you may move the Court for appointment as lead
plaintiff by no later than March 22, 2016. A lead plaintiff is a
representative party who acts on behalf of other class members in
directing the litigation. Your share of any recovery in the action
will not be affected by your decision of whether to seek
appointment as lead plaintiff. You may retain Lieff Cabraser, or
other attorneys, as your counsel in the action.
HeartWare investors who wish to learn more about the action and
how to seek appointment as lead plaintiff should click here or
contact Sharon M. Lee of Lieff Cabraser toll-free at
1-800-541-7358.
The action alleges that, throughout the Class Period, defendants
falsely claimed to have addressed numerous manufacturing and other
regulatory failures identified by the U.S. Food and Drug
Administration (“FDA”) regarding HeartWare’s Miniaturized
Ventricular Assist Device (“MVAD”).
On September 1, 2015, HeartWare revealed major problems that
would impede the advancement of MVAD’s approval. On this news,
HeartWare’s stock price fell nearly 21%, to close at $64.82 per
share on September 2, 2015.
On October 12, 2015 HeartWare disclosed that patients in the
MVAD trial had suffered adverse events and that the trial would be
further delayed. On this news, HeartWare’s stock price fell nearly
30%, to close at $35.21 per share on October 13, 2015.
On January 11, 2016, HeartWare admitted that problems with the
MVAD had resulted in major problems in nearly half the patients in
the trial who had been implanted with the device and that the trial
would be suspended until further notice. On this news, HeartWare
stock price dropped over 35%, to close at $26.50 per share on
January 12, 2016.
About Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP is a nationally
recognized law firm committed to advancing investor rights and
promoting corporate responsibility.
For thirteen years, the National Law Journal has selected Lieff
Cabraser as one of the top plaintiffs’ law firms in the nation.
Best Lawyers and U.S. News have also named Lieff Cabraser as a “Law
Firm of the Year” each year the publications have given this award
to law firms.
For more information about Lieff Cabraser and the firm’s
representation of investors, please visit
http://www.lieffcabraser.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160209006800/en/
Source/Contact for Media Inquiries
Only:Lieff Cabraser Heimann & Bernstein, LLPSharon M.
Lee, 800-541-7358
Heartware International, Inc. (MM) (NASDAQ:HTWR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heartware International, Inc. (MM) (NASDAQ:HTWR)
Historical Stock Chart
From Sep 2023 to Sep 2024